First-in-human Trial (original) (raw)
Latest News for: first-in-human trial
Matricelf Advances Toward First in Human Trial with Initiation of GMP Manufacturing Program
The Facts 09 Jun 2026
(TASE.
First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer
PR Newswire 12 May 2026
The study, titled "First-In-Human Trial ... Peer-reviewed paper.First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma .
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy ...
Nasdaq Globe Newswire 11 May 2026
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita� in pivotal development for post-GLP-1 weight maintenance and Rejuva� entering first-in-human studies for type 2 diabetes ... .
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands:
Hastings Tribune 11 May 2026
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita®in pivotal development for post-GLP-1 weight maintenance and Rejuva®entering first-in-human studies for type 2 diabetes ... .
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes (Form 8-K) (Fractyl Health Inc)
Public Technologies 11 May 2026
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands ... The Phase 1/2 study is an open-label, multicenter, single-ascending-dose, first-in-human trial evaluating the ...
CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial ...
Lebanon Express 29 Apr 2026
PASADENA, Calif., April 28, 2026 /PRNewswire/ -- AcuraStem, a ...
CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial for ALS and FTD
PR Newswire 28 Apr 2026
... Institute for Regenerative Medicine (CIRM) has awarded the company $7.5 million in grant funding to support the advancement of its lead clinical candidate, AS-241, toward first–in–human testing.
Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- ...
Nasdaq Globe Newswire 23 Apr 2026
... company’s first-in-human (FIH) trial of their investigational Nectero EAST® System.
- 1
Article Search
tools
You can search using any combination of the items listed below.
Language:
Sort:
Indexed:
Search:
Duplicates: